Literature DB >> 8691979

Further evidence that naloxone acts as an inverse opiate agonist: implications for drug dependence and withdrawal.

S L Cruz1, J E Villarreal, N D Volkow.   

Abstract

To test if naloxone behaved as an inverse agonist rather than as an antagonist we evaluated its responses in guinea-pig ilea with and without morphine (480 nM, 24 h). In control ilea, naloxone (100 nM) had no effect. In morphine-treated ilea, naloxone as a bolus, but not as an infusion, elicited an abstinence response. Preadministration of naloxone blocked the response to subsequent administrations. Similarly, naloxone failed to produce an abstinence response in ilea pretreated with kappa compounds (bremazocine, U50488 or xorphanol 100 nM) or with kinase inhibitors (H7 or H8 30 microM). These findings can be interpreted in the light of the two-state receptor model if naloxone behaves as an inverse agonist: Incubation with morphine increased the active state of receptors making them susceptible to the inverse agonist (naloxone); exposure to naloxone favored the inactive conformation making them insensitive to further administration of naloxone; kappa compounds behaved as antagonists preventing the response to naloxone; and kinase inhibitors interfered with the active conformation making the system insensitive to naloxone. According to this model, dependence can be viewed as an overexpression of the active receptors and withdrawal as an abrupt change from the active to the inactive state.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8691979     DOI: 10.1016/0024-3205(96)00250-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

Review 1.  Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery.

Authors:  R A de Ligt; A P Kourounakis; A P IJzerman
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 2.  Neuropsychological consequences of opiate use.

Authors:  Staci A Gruber; Marisa M Silveri; Deborah A Yurgelun-Todd
Journal:  Neuropsychol Rev       Date:  2007-08-10       Impact factor: 7.444

3.  Beta-agonist-induced constitutive beta(2)-adrenergic receptor activity in bovine tracheal smooth muscle.

Authors:  B de Vries; H Meurs; A F Roffel; C R Elzinga; B H Hoiting; M M de Vries; J Zaagsma
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

4.  Inverse agonism and its therapeutic significance.

Authors:  Gurudas Khilnani; Ajeet Kumar Khilnani
Journal:  Indian J Pharmacol       Date:  2011-09       Impact factor: 1.200

5.  Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors.

Authors:  Parham Gharagozlou; Hasan Demirci; J David Clark; Jelveh Lameh
Journal:  BMC Neurosci       Date:  2002-11-18       Impact factor: 3.288

6.  Enhancement of Meditation Analgesia by Opioid Antagonist in Experienced Meditators.

Authors:  Lisa M May; Peter Kosek; Fadel Zeidan; Elliot T Berkman
Journal:  Psychosom Med       Date:  2018 Nov/Dec       Impact factor: 4.312

Review 7.  Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?

Authors:  Mark S Gold; David Baron; Abdalla Bowirrat; Kenneth Blum
Journal:  J Neurol Sci       Date:  2020-09-15       Impact factor: 3.181

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.